12:00 AM
Jul 25, 2005
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tenofovir disoproxil fumarate: Phase III started

GILD began the double-blind, international, Phase III Study 102 trial in about 300 patients with HBeAg-negative/anti-HBe positive chronic HBV. In the trial 200 patients will receive 300 mg...

Read the full 120 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >